Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypoestoxide (HE) is a natural diterpene and an active pharmaceutical ingredient (API) isolated and purified from the herbal plant Hypoestes rosea. It is characterized by a complex bicyclo [9,3,1] pentadecane ring system, two epoxide moieties, an alpha beta-unsaturated ketone, an acetylated alcohol group, and seven stereo centers, making it non-synthesizable in the laboratory. Hypoestoxide exhibits a range of biological activities, including anti-malarial, anti-inflammatory, anti-cancer, anti-viral, and anti-Parkinson's disease properties. It is considered non-toxic and non-mutagenic. Developed by Immune Modulation, Inc., it is being investigated for its therapeutic potential in various conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hypoestoxide.